Deep research. High conviction.
We do deep thematic research long before we invest—mapping technologies, markets, and inflection points with help from leading experts.
It sharpens our conviction, but more importantly, it lets us show up in the boardroom as true partners. We work to earn the right to be your first call when decisions really matter.
G2 Playbook: Raising Capital
We have a Playbook at G2 which we’ve developed while investing together for over a decade in more than a hundred companies.
Kelly Golden Joins G2 Venture Partners as Director of Investor Relations
.avif)
Kelly joins G2 Venture Partners as Director of Investor Relations. Prior to joining G2, Kelly was an Executive Director at UBS where she spent nine years on the Capital Introduction team. At UBS, Kelly was responsible for leading Cap Intro efforts with institutional investors on the West Coast and in Texas and providing in-depth consulting and strategic marketing advice to UBS's global hedge fund clients.
Synthetic Biology: From Promise to Profits
In 2010, a synthetic biology company set out to revolutionize the therapeutics space. It touted a synthetic messenger RNA platform that could drive an expansive pipeline of healthcare products.
The Battle for EV Supremacy: Will Tesla Win This Decade?
Demand for EVs has never been stronger, across all vehicle categories — spurred by all-time highs in gas prices and pushes for decarbonization among corporations and consumers.